Last reviewed · How we verify
NCT06899633
Multicenter, Observational, Descriptive Study of the Diagnosis, Course and Treatment of Patients With SLE in Routine Practice in Kazakhstan: a Registry Study With Retrospective and Prospective Components.
trial in Description of SLE Activity in Patients in Routine Practice in the Republic of Kazakhstan in 509 participants. Participants enrolled and being followed up; not accepting new ones.
28 February 2027
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 509 |
| Start date | 15 May 2025 |
| Primary completion | 28 February 2027 |
| Estimated completion | 28 February 2027 |
| Sites | 12 locations across Kazakhstan |
Conditions studied
- Description of SLE Activity in Patients in Routine Practice in the Republic of Kazakhstan — all drugs for Description of SLE Activity in Patients in Routine Practice in the Republic of Kazakhstan →
- Description of the Course of SLE in Patients in the Republic of Kazakhstan — all drugs for Description of the Course of SLE in Patients in the Republic of Kazakhstan →
- Description of Methods and Approaches to the Treatment of Patients With SLE in the Republic of Kazakhstan — all drugs for Description of Methods and Approaches to the Treatment of Patients With SLE in the Republic of Kazakhstan →
Sponsor
AstraZeneca — full company profile →
Who can join
18 and older, any sex, with Description of SLE Activity in Patients in Routine Practice in the Republic of Kazakhstan or Description of the Course of SLE in Patients in the Republic of Kazakhstan. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multicenter, observational, descriptive study of the diagnosis, course and treatment of patients with SLE in routine practice in Kazakhstan: a registry study with retrospective and prospective components.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06899633
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06899633 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 17 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06899633.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing